Drug-drug interaction between emtricitabine/tenofovir alafenamide (FTC/TAF)-based PrEP and feminizing hormones in transgender women: peripheral blood mononuclear cells and urine analysis from the iFACT3 studyOral abstract session with live Q&AHIV prevention research
Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescentsOral abstract session with live Q&AAntiretroviral therapies and clinical issues in infants, children and adolescents
Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3DOral abstract session with live Q&AAntiretroviral therapies and clinical issues in adults
In vivo genome engineering of human T cells results in ART-free control of HIV-1 in humanized miceOral abstract session with live Q&ANovel treatment and prevention strategies
Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIVOral abstract session with live Q&AAntiretroviral therapies and clinical issues in adults
Protective efficacy of intranasal vaccination with a Sendai virus vector expressing a spike antigen against SARS-CoV-2 infection in miceOral abstract session with live Q&ASARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies
Reporting, prevention and response of gender based violence against men who have sex with men in Taraba State, NigeriaOral abstract session with live Q&ASocial and behavioural aspects and approaches to HIV
COVID-19 vaccine effectiveness by HIV status and injection drug use historyOral abstract session with live Q&AEpidemiology of COVID-19
Gut memory CD4+ T cells from people with HIV on suppressive ART express high levels of intracellular HIV sensorsOral abstract session with live Q&AHIV pathogenesis
Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018)Oral abstract session with live Q&AClinical complications of HIV and antiretroviral therapy
1 - 10 of 1322 items